Chair Fred Lublin, MD, FAAN, FANA Saunders Family Professor of Neurology Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Co-Chief Editor, Multiple Sclerosis and Related Disorders Icahn School of Medicine at Mount Sinai New York, NY
Faculty Amy Perrin Ross, APN, MSN, CNRN, MSCN Neuroscience Program Coordinator Loyola University Medical Center Maywood, IL
Bryan Walker, MHS, PA-C Assistant Professor Associate Director, Didactic Curriculum The George Washington University School of Medicine and Health Science Physician Assistant Program Washington, DC
EJ Levy Founder and President MS Hope for a Cure New York, NY
AMA PRA Category 1 Credit TM
Nurses: 1.3 contact hours Medium
An estimated 350,000 to 500,000 people in the United States are currently diagnosed with MS, a chronic neurologic disorder with potential for substantial negative impact on quality of life. Treatment is focused on returning function after an attack, preventing new attacks, and preventing disability. The management of MS is increasingly challenging due to heterogeneity in the pathogenesis of MS, wide variation in the clinical course for each patient, an increasing number of therapeutic options, and evolving best practices. A lack of knowledge about individualized therapy, available and emerging therapies, and clinician-patient relationships can result in suboptimal therapeutic outcomes among patients with MS.
This activity is co-provided by Penn State College of Medicine, Postgraduate Institute for Medicine, and MCM Education
This activity is intended for physicians, PAs, NPs, and RNs specializing in neurology or MS
Upon completion of this educational activity, the participant should be able to:
Explain best practices to support an early, accurate diagnosis of MS.
Discuss current best practices in the management of common MS symptoms, such as depression, fatigue, cognitive dysfunction, and mobility impairment.
Compare current evidence for the efficacy and safety of FDA-approved MS disease-modifying therapies for patients with relapsing-remitting MS.
Describe advances in the use of markers and imaging technologies to monitor MS disease progression and tailor the use of disease-modifying therapy for individual patients.
Summarize emerging efficacy and safety data for investigational therapies in late stages of development for the treatment of MS.
Provide appropriate care and counsel for patients and their families.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Fred Lublin, MD, FAAN, FANA has disclosed the following:
Research Funding: Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; Transparency Life Sciences; NIH; NMSS
Advisory Board: Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc., Novartis, Teva Neuroscience, Actelion, Sanofi-Aventis, Acorda, Questcor, Roche, Genentech, Celgene, Johnson & Johnson, Revalesio, Coronado Bioscience, Genzyme, MedImmune, Bristol-Myers Squibb, Xenoport, Receptos, Forward Pharma, to-BBB technologies
Stock Ownership: Cognition Pharmaceuticals, Inc.
Amy Perrin Ross, APN, MSN, CNRN, MSCN has disclosed the following:
Consultant: Acorda Therapeutics, Bayer HealthCare Pharmaceuticals, EMD Serono, Genzyme, Novartis, Questcor, Teva
Speakers Bureau: Acorda Therapeutics, Bayer HealthCare Pharmaceuticals, EMD Serono, Genzyme, Novartis, Questcor, Teva
Bryan Walker, MHS, PA-C has disclosed the following:
Stock Ownership: Biogen Idec
EJ Levy has nothing to disclose.
Elisabeth Lucassen, MD, Penn State CME Reviewer, has disclosed the following:
Speakers Bureau: Biogen Idec, EMD Serono, Genzyme, Novartis, Teva
Penn State staff involved in the development and review of this activity have nothing to disclose.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, Postgraduate Institute for Medicine, and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5657-15-T.
This educational activity for 1.3 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A statement of credit will be issued only upon receipt of a completed online activity evaluation.
For questions regarding the CNE/nursing credit, contact Postgraduate Institute for Medicine at (800) 423-3576 or firstname.lastname@example.org .
Credit is awarded to participants who score 75% or better on the post-test.
The online activity will take approximately 60 minutes to complete. Commercial Support Statements
Supported by independent educational grants from Teva Pharmaceuticals and Novartis Pharmaceuticals Corporation.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, Postgraduate Institute for Medicine, Teva, or Novartis. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.